© geralt/pixabay.com

Evosep APS has inked a $40m funding deal with Novo Holdings A/S that is aimed to advance standardised clinical LC-MS-based drug discovery and diagnostic multi-marker tests.

Exevir BIO executive team at EIB. © EIB/Exevir BIO

With the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.

© Synaffix BV

Rational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.

© Ethris GmbH

Cipla EU Ltd is going to make an equity investment of €15m in Ethris GmbH, a specialist for respiratory  delivery of therapeutic mRNAs.

© pixabay/prawny

Scientists from the University of Basel and the University Hospital Basel have found that two bacterial species may indicate multiple sclerosis-associated lymphopenia.

© fernandozhiminaicela/pixabay.com

CEPI fights the betacoronaviruses by funding Ethris GmbH and DIOSynVax Ltd and their joint effort to advance their work on an mRNA vaccine.

© qimono/pixabay.com

Atara Biotherapeutics Inc. and Pierre Fabre SA announced the approval of Tabelecleucel, a therapy for a rare and potentially fatal malignancy.

@ Numares

The European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction.

IBD_2023.png

"Solutions for an endangered planet" is what industrial biotechnology seeks and offers. Technical innovations based on nature’s toolbox are intended to help "biologise" industry – in other words, to adapt it to the natural cycles of our planet.

© Triggermouse/pixabay.com

MinervaX inks €72m financing deal with Novo Holdings REPAIR Impact Fund to develop a vaccine against Group B Streptococcus.